Multidrug therapy
Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDTCT-BR): adverse effects approach
... Dona Libânia (Fortaleza, Ceará) and Alfredo da Matta (Manaus, Amazonas). Patients were classified as PB and MB according to the number of skin lesions and randomly assigned to U-MDT or R-MDT sub-groups. Further protocol ...
8
Uniform multidrug therapy for leprosy patients in Brazil (U-MDTCT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients
... of multidrug therapy for leprosy in the 80’s, different classification criteria for leprosy patients have been proposed and treatment has been progressively ...
19
Brazilian clinical trial of uniform multidrug therapy for leprosy patients - the correlation between clinical disease types and adverse effects
... leprosy therapy occurred in 1981 when the World Health Organization (WHO) recom- mended using multidrug therapy (MDT), with dapsone and rifampicin for six months for paucibacillary (PB) pa- tients ...
5
A clinical trial for uniform multidrug therapy for leprosy patients in Brazil: rationale and design
... uniform multidrug therapy (U-MDT) for leprosy patients (LPs) in Brazil is a ran- domised, open-label clinical trial to evaluate if the effectiveness of U-MDT for leprosy equals the regular regimen, to ...
219
A clinical trial for uniform multidrug therapy for leprosy patients in Brazil : rationale and design
... uniform multidrug therapy (U-MDT) for leprosy patients (LPs) in Brazil is a ran- domised, open-label clinical trial to evaluate if the effectiveness of U-MDT for leprosy equals the regular regimen, to ...
220
Brazilian clinical trial of uniform multidrug therapy for leprosy patients : the correlation between clinical disease types and adverse effects
... leprosy therapy occurred in 1981 when the World Health Organization (WHO) recom- mended using multidrug therapy (MDT), with dapsone and rifampicin for six months for paucibacillary (PB) pa- tients ...
6
Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy
... This cross-sectional retrospective study evaluated 440 leprosy patients; 57% (251/440) had leprosy reactions during and/or after multidrug therapy, 80.5% (202/251) of whom presented with multibacillary ...
8
DISABILITY IN LEPROSY – A RETROSPECTIVE, DESCRIPTIVE AND ANALYTIC STUDY OF 243 PATIENTS TREATED BEFORE AND AFTER THE INTRODUCTION OF MULTIDRUG THERAPY BY THE WHO
... analytic study of 243 patients distributed in two groups: 164 “old” patient” and 79 “new” patients. Sex, age at diagnosis, time between the onset of symptoms and diagnosis, clinical forms, bacilloscopy, early ...
7
Arq. NeuroPsiquiatr. vol.70 número6
... the developing and underdeveloped countries of tropical and subtropical areas, and is infrequent in the developed coun- tries. It usually afects the skin, the nerves, the nasal mucosa and the eyes. he clinical and the ...
3
Epidemiol. Serv. Saúde vol.26 número4
... Acronyms: LCP, Leprosy Control Program; Sinan, Information System for Notiafible Diseases; ES, epidemiological surveillance; MDT, multidrug therapy-; MC, multibacillary; PB, paucibacill[r] ...
17
Adalberto Rezende Santos, Vivian Balassiano, Maria Leide W Oliveira, Marcia Aparecida da Silva Pereira, Patricia Barros Santos, Wim Maurits Degrave, Philip Noel Suffys
... leprosy multidrug therapy (MDT), were submitted to traditional diagnostic procedures for leprosy and to polymerase chain reaction (PCR) analysis of different clinical samples for detection of Mycobacterium ...
6
Anti-b2-glycoprotein I antibodies are highly prevalent in a large number of brazilian leprosy patients
... The objectives of this study were to determine the prevalence of aCL and anti-b 2 GPI antibodies in a large number of Amazon leprosy patients taking multidrug therapy (MDT) and in comple[r] ...
8
Positividade sorológica antiPGL-I em contatos domiciliares e peridomiciliares de hanseníase em área urbana.
... Lombardi C, Zicker F. Changes in leprosy pattern after multidrug therapy implementation. Ministério da Saúde. Secretaria de Política da Saúde. Departamento de Atenção Básica. Área Técni[r] ...
6
Review Article Mortality in patients with multidrug-resistant
... Pseudomonas aeruginosa is the leading cause of nosocomial infections with high mortality rates owing to the limited therapeutic options for multidrug-resistant Pseudomonas aeruginosa (MDRPA) and ...
6
Clonagem, expressão, purificação e caracterização da enzima citidina monofosfato quinase de Mycobacterium tuberculosis
... D -thiogalactopyranoside; MDR-TB, multidrug-resistant tuberculosis; MtCMK, cytidine monophosphate kinase from Mycobacterium tuberculosis ; NMP, nucleoside monophosphate; NMP kinases, [r] ...
71
Molecular characterization of multidrug-resistant Klebsiella pneumoniae isolates
... NC). Multidrug resistance was defined as non-susceptibility to at least one agent in three or more antimicrobial categories according to the breakpoints recommended by the Clinical and Labora- tory Standards ...
10
Positive Epistasis Drives the Acquisition of Multidrug Resistance
... Our results highlight the importance of determining the costs of single and multiple resistances and, accordingly ordering allele combinations by the degree of epistasis they exhibit. Given that at the present time, ...
9
ACTION OF NEWER DISINFECTANTS ON MULTIDRUG RESISTANT BACTERIA
... ABSTRACT: BACKGROUND: Current procedures for infection control in hospital environments have not been successful in curbing the rise in infections by multi-drug-resistant (MDR) pathogens. Emergence of resistance to ...
17
Beyond multidrug-resistant tuberculosis in Europe: a TBNET study
... challenge to TB control in Europe. We evaluated second- line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug- resistant, pre-extensively drug-resistant (pre-XDR-TB) ...
5
Antineoplastic therapy - multidrug resistance
... Vinca alkaloids prevent the formation of tubulin dimers, and their incorporation into the mitotic spindle (spindle apparatus). Side effects include neurotoxicity, with manifestation such as ataxia, paresthesia and loss ...
62